WallStSmart

Fold Holdings, Inc. Class A Common Stock (FLD)vsMorgan Stanley (MS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Morgan Stanley generates 956178% more annual revenue ($70.30B vs $7.35M). MS leads profitability with a 24.0% profit margin vs 3.9%. FLD trades at a lower P/E of 1.8x. MS earns a higher WallStSmart Score of 76/100 (B+).

FLD

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 3.0Value: 8.3Quality: 5.0
Piotroski: 4/9

MS

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.5Value: 10.0Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FLDUndervalued (+94.7%)

Margin of Safety

+94.7%

Fair Value

$28.08

Current Price

$1.47

$26.61 discount

UndervaluedFair: $28.08Overvalued
MSUndervalued (+59.3%)

Margin of Safety

+59.3%

Fair Value

$407.18

Current Price

$165.65

$241.53 discount

UndervaluedFair: $407.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FLD3 strengths · Avg: 10.0/10
P/E RatioValuation
1.8x10/10

Attractively priced relative to earnings

Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
41.2%10/10

Revenue surging 41.2% year-over-year

MS6 strengths · Avg: 8.8/10
Market CapQuality
$263.03B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Profit MarginProfitability
24.0%9/10

Keeps 24 of every $100 in revenue as profit

P/E RatioValuation
16.2x8/10

Attractively priced relative to earnings

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

EPS GrowthGrowth
20.7%8/10

Earnings expanding 20.7% YoY

Areas to Watch

FLD4 concerns · Avg: 2.8/10
Market CapQuality
$52.25M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.8%3/10

ROE of 2.8% — below average capital efficiency

Profit MarginProfitability
3.9%3/10

3.9% margin — thin

Free Cash FlowQuality
$-5.03M2/10

Negative free cash flow — burning cash

MS3 concerns · Avg: 3.0/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Free Cash FlowQuality
$-4.60B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : FLD

The strongest argument for FLD centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 41.2% demonstrates continued momentum.

Bull Case : MS

The strongest argument for MS centers on Market Cap, Operating Margin, Profit Margin. Profitability is solid with margins at 24.0% and operating margin at 38.6%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : FLD

The primary concerns for FLD are Market Cap, Return on Equity, Profit Margin. Thin 3.9% margins leave little buffer for downturns.

Bear Case : MS

The primary concerns for MS are PEG Ratio, Piotroski F-Score, Free Cash Flow.

Key Dynamics to Monitor

FLD profiles as a hypergrowth stock while MS is a mature play — different risk/reward profiles.

MS carries more volatility with a beta of 1.21 — expect wider price swings.

FLD is growing revenue faster at 41.2% — sustainability is the question.

FLD generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

MS scores higher overall (76/100 vs 63/100), backed by strong 24.0% margins and 11.0% revenue growth. FLD offers better value entry with a 94.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fold Holdings, Inc. Class A Common Stock

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Fold Holdings, Inc. (FLD) is a forward-thinking biotechnology company harnessing advanced research methodologies to pioneer innovative therapies aimed at treating severe genetic and rare diseases. With a robust product pipeline supported by proprietary technologies, Fold is committed to reshaping the drug development landscape. The firm actively engages in strategic partnerships that enhance its market access and growth prospects, positioning it as a significant player in the biotechnology sector. By maintaining a strong focus on scientific excellence and patient-centric solutions, Fold Holdings is well-equipped for sustainable growth and value creation in the dynamic healthcare market.

Visit Website →

Morgan Stanley

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Morgan Stanley is an American multinational investment bank and financial services company headquartered at 1585 Broadway in the Morgan Stanley Building, Midtown Manhattan, New York City.

Want to dig deeper into these stocks?